Claims
- 1. An isolated, enriched, or purified nucleic acid molecule encoding an hWART polypeptide.
- 2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a nucleotide sequence that
(a) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:4; (b) is the complement of the nucleotide sequence. of (a); (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally occurring hWART polypeptide; (d) encodes an hWART polypeptide having the full length amino acid sequence of the sequence set forth in SEQ ID NO:3 or SEQ ID NO:4, except that it lacks one or more of the following segments of amino acid residues:12-45, 55-151, 236-377, 404-520, 555-559, 601-702, 691-998, 1011-1086 of SEQ ID NO:3, or 1-33, 43-139, 342-466, 467-480, 514-518, 974-1048 of SEQ ID NO:4; (e) is the complement of the nucleotide sequence of (d); (f) encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:4 from amino acid residues 12-45, 55-151, 236-377, 404-520, 555-559, 601-702, 691-998, 1011-1086 of SEQ ID NO:3, or 1-33, 43-139, 342-466, 467-480, 514-518, 974-1048 of SEQ ID NO:4; (g) is the complement of the nucleotide sequence of (f); (h) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:4, except that it lacks one or more of the domains selected from the group consisting of an N-terminal domain, a catalytic domain, and a C-terminal domain; or (i) is the complement of the nucleotide sequence of (h).
- 3. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is isolated, enriched, or purified from a mammal.
- 4. The nucleic acid molecule of claim 3, wherein said mammal is a human.
- 5. The nucleic acid molecule of claim 1, further comprising a vector or promoter effective to initiate transcription in a host cell.
- 6. A nucleic acid probe for the detection of nucleic acid encoding an hWART polypeptide in a sample.
- 7. The probe of claim 6 wherein said polypeptide comprises at least 46 contiguous amino acids of the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:4.
- 8. A nucleic acid molecule comprising one or more regions that encode an hWART polypeptide or an hWART domain polypeptide, wherein said hWART polypeptide or said hWART domain polypeptide is fused to a non-WART polypeptide.
- 9. A recombinant cell comprising a nucleic acid molecule encoding either
(a) an hWART polypeptide; (b) an hWART domain polypeptide; or (c) an hWART polypeptide or hWART domain polypeptide fused to a non-WART polypeptide.
- 10. An isolated, enriched or purified hWART polypeptide.
- 11. The polypeptide of claim 10, wherein said polypeptide is a fragment of the protein encoded by the full length amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:4.
- 12. The polypeptide of claim 10, wherein said polypeptide comprises an amino acid sequence having
(a) the full length amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:4; (b) the full length amino acid sequence of the sequence set forth in SEQ ID NO:3 or SEQ ID NO:4, except that it lacks one or more of the following segments of amino acid residues:12-45, 55-151, 236-377, 404-520, 555-559, 601-702, 691-998, 1011-1086 of SEQ ID NO:3, or 1-33, 43-139, 342-466, 467-480, 514-518, 974-1-048 of SEQ ID NO:4; (c) the amino acid sequence-set forth in SEQ ID NO:3 or SEQ ID NO:4 from amino acid residues 12-45, 55-151, 236-377, 404-520, 555-559, 601-702, 691-998, 1011-1086 of SEQ ID NO:3, or 1-33, 43-139, 342-466, 467-480, 514-518, 974-1048 of SEQ ID NO:4; or (d) the full length amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:4 except that it lacks one or more of the domains selected from the group consisting of an N-terminal domain, a catalytic domain, and a C-terminal domain.
- 13. An antibody or antibody fragment having specific binding affinity to an hWART polypeptide or an hWART domain polypeptide.
- 14. A hybridoma which produces an antibody having specific binding affinity to an hWART polypeptide.
- 15. A method for identifying a substance capable of modulating hWART activity comprising the steps of:
(a) contacting an hWART polypeptide with a test substance; and (b) determining whether said substance alters the activity of said polypeptide.
- 16. A method for identifying a substance capable of modulating hWART function in a cell comprising the steps of:
(a) expressing an hWART polypeptide in a cell; (b) adding a test substance to said cell; and (c) monitoring a change in either cell phenotype, cell proliferation, cell differentiation, hWART catalytic activity, or the interaction between an hWART polypeptide and a natural binding partner.
- 17. A method of preventing or treating an abnormal condition by administering to a patient in need of such treatment a compound that modulates the function of an hWART polypeptide.
- 18. The method of claim 17, wherein said abnormal condition involves an abnormality in hWART signal transduction pathway.
- 19. The method of claim 18, wherein said abnormal condition is cancer.
- 20. The method of claim 17, wherein said compound modulates the function of an hWART polypeptide in vitro.
- 21. A kit, comprising the compound of claim 17 and a protocol for the use of said compound.
- 22. The kit of claim 21, wherein said protocol is approved by the Food and Drug Administration.
RELATED APPLICATIONS
[0001] This application is related to and claims priority to the U.S. Provisional Application Serial No. 60/072,023, filed on Jan. 21, 1998, by Plowman et al., and entitled “HUMAN ORTHOLOGUES OF WART” (Lyon & Lyon Docket No. 224/006), which is hereby incorporated by reference herein in its entirety, including any drawings.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60072023 |
Jan 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09233857 |
Jan 1999 |
US |
Child |
10284130 |
Oct 2002 |
US |